FDA PMA FDA Class 3 30-Day Notice Accepted 🇺🇸 United States

Drug Eluting Permanent Left Ventricular (Lv) Pacemaker Electrode

PMA: P010015 · Supplement: S196 · Decision Apr 11, 2013
Classifications
1
FEI Numbers
22
Registration Numbers
22

Basic Information

Device Name
Drug Eluting Permanent Left Ventricular (Lv) Pacemaker Electrode
Trade Name
CONSULTA CRT-P, SYNCRA CRT-P
PMA Number
P010015
Supplement Number
S196
Device Class
FDA Class 3
Product Code
OJX
Generic Name
Drug eluting permanent left ventricular (lv) pacemaker electrode
Medical Specialty
Unknown
Advisory Committee
Cardiovascular
Decision
30-Day Notice Accepted
Decision Code
OK30
Decision Date
April 11, 2013
Date Received
March 27, 2013
Supplement Type
30-Day Notice
Supplement Reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Expedited Review
N

Advisory Committee Statement

REDUCTION OF THE HYBRID BURN-IN TIME FOR THE ADVISA DR, ADVISA DR MRI IPGS, REVO MRI IPG, CONSULTA AND SYNCRA CRT-PS.

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
OJX Drug Eluting Permanent Left Ventricular (Lv) Pacemaker Electrode